NCI Director And Former Dx Start-Up Founder Sharpless Will Helm FDA
After a week of speculation as to who will succeed US FDA Commissioner Scott Gottlieb when he steps down next month, Health and Human Services Secretary Alex Azar announced during a congressional hearing that National Cancer Institute Director Ned Sharpless will step in as acting commissioner. One note of medtech interest in Sharpless' bio: he was a co-founder of a diagnostics company.
You may also be interested in...
The Trump administration is seriously considering three candidates to become US Food and Drug Administration commissioner when the legally mandated 210-day term of acting commissioner Norman “Ned” Sharpless ends on 4 November.
Speaking to an audience in Washington, DC, the acting commissioner of the US FDA said he’d like to be nominated and confirmed to the job permanently. However, given the current political climate that may not happen until after the 2020 presidential election.
Following his recent talk at the National Press Club on reimbursement issues, former US FDA Commissioner Scott Gottlieb told Medtech Insight a new breakthrough device rule proposed by the Medicare agency CMS is good but will still be economically unfeasible for many hospitals. Instead, he says new frameworks need to be developed for the new kinds of technologies coming to market.